Benign female reproductive system neoplasm

Summary

Benign female reproductive system neoplasm (MONDO:0000624) is a cancer (an umbrella term covering 7 Mondo subtypes) and 8 clinical trials. Top therapeutic interventions include parecoxib and simethicone. A subtype of benign reproductive system neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 7 Mondo subtypes
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign female reproductive system neoplasm
Mondo ID	MONDO:0000624
DOID	DOID:0060086
NCIT	C4934
UMLS	C0744514
MedGen	152872
Anatomy (UBERON)	UBERON:0003134
Is cancer (heuristic)	yes

Also known as: benign female reproductive system neoplasm · benign female reproductive system tumor · benign female reproductive system tumour · benign gynecologic neoplasm · benign gynecologic tumor · benign gynecologic tumour · female reproductive organ benign neoplasm

Disease family

This is a subtype of benign reproductive system neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › benign reproductive system neoplasm › benign female reproductive system neoplasm

Related subtypes (5): benign male reproductive system neoplasm, paratesticular lipoma, adrenal rest tumor, benign neoplasm of pituitary gland, sex cord-stromal benign neoplasm

Subtypes (7): uterine benign neoplasm, vulvar benign neoplasm, fallopian tube benign neoplasm, ovarian benign neoplasm, benign vaginal neoplasm, adenomyoma, adenofibroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03009604	PHASE3	UNKNOWN	Does Simethicone Improve Operative Field in Gynecological Operations
NCT05629611	Not specified	RECRUITING	Efficacy and Safety Evaluation of Vi-sealer
NCT06802198	Not specified	NOT_YET_RECRUITING	A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes
NCT01566669	Not specified	COMPLETED	Efficacy and Safety of Parecoxib on Morphine Patient-controlled Epidural Analgesia (PCEA) After Gynecologic Surgery
NCT02728999	Not specified	TERMINATED	Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?
NCT03548831	Not specified	COMPLETED	Comparative Study of LAVH and Minilaparotomy Hysterectomy
NCT03645304	Not specified	UNKNOWN	Postoperative Analgesic Efficacy of Continuous Wound Infusion After Laparoscopy
NCT05710601	Not specified	COMPLETED	Effects of Tissue Sealers on Minor Laparoscopic Procedures Between Obstetrics and Gynecology Residents

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PARECOXIB	4	2
SIMETHICONE	4	1